ClinicalTrials.gg
Active, not recruitingNCT07291232Updated Nov 5, 2026

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

A Phase 1 interventional study of ABBV-295 and Placebo in Obesity, sponsored by AbbVie. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Updated Nov 5, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • ABBV-295
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 80 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 30.0 to ≤ 45.0 kg/m2 after rounding to the tenths decimal at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters) with or without weight related stable comorbidities (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
  • A female who is not pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 60 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
  • ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
  • Participant has taken a medication for the purpose of treating obesity or has been enrolled in an obesity trial within 180 days prior to study treatment administration.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    ABBV-295 or Placebo-Group 1

    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.

    Drug: ABBV-295 · Drug: Placebo

  • Experimental
    ABBV-295 or Placebo-Group 2

    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.

    Drug: ABBV-295 · Drug: Placebo

  • Experimental
    ABBV-295 or Placebo-Group 3

    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.

    Drug: ABBV-295 · Drug: Placebo

  • Experimental
    ABBV-295 or Placebo-Group 3 Extension

    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks.

    Drug: ABBV-295 · Drug: Placebo

  • Experimental
    ABBV-295 or Placebo-Group 4

    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.

    Drug: ABBV-295 · Drug: Placebo

  • Experimental
    ABBV-295 or Placebo-Group 4 Extension

    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks.

    Drug: ABBV-295 · Drug: Placebo

  • Experimental
    ABBV-295 or Placebo-Group 5

    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks.

    Drug: ABBV-295 · Drug: Placebo

  • Experimental
    ABBV-295 or Placebo-Group 6

    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks.

    Drug: ABBV-295 · Drug: Placebo

Interventions

  • Subcutaneous Injections

  • DrugPlacebo

    Subcutaneous Injections

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Up to approximately 194 days

  2. Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements

    Number of participants with abnormal change from baseline in vital sign measurements like heart rate, systolic and diastolic blood pressure will be assessed.

    Time frame: Up to approximately 194 days

  3. Number of Participants with Change from Baseline in Electrocardiogram (ECG)

    12-lead resting ECG will be recorded.

    Time frame: Up to approximately 194 days

  4. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed

    Number of participants with abnormal change in clinical laboratory test results like biochemistry, hematology will be assessed.

    Time frame: Up to approximately 194 days

  5. Maximum Observed Plasma Concentration (Cmax) of ABBV-295

    Cmax of ABBV-295

    Time frame: Up to approximately 194 days

  6. Time to Cmax (Tmax) of ABBV-295

    Tmax of ABBV-295

    Time frame: Up to approximately 194 days

  7. Trough plasma concentration (Ctrough) of ABBV-295

    Ctrough of ABBV-295

    Time frame: Up to approximately 194 days

  8. Apparent terminal phase elimination rate constant (BETA) of ABBV-295

    BETA of ABBV-295

    Time frame: Up to approximately 194 days

  9. Terminal phase elimination half-life (t1/2) of ABBV-295

    t1/2 of ABBV-295

    Time frame: Up to approximately 194 days

  10. Area under the plasma concentration-time curve (AUC) of ABBV-295

    AUC of ABBV-295

    Time frame: Up to approximately 194 days

  11. Area under the plasma concentration-time curve over the dosing interval (AUCtau) of ABBV-295

    AUCtau of ABBV-295

    Time frame: Up to approximately 194 days

  12. Dose Normalized Cmax of ABBV-295

    Dose normalized Cmax of ABBV-295 will be assessed.

    Time frame: Up to approximately 194 days

  13. Dose Normalized AUC of ABBV-295

    Dose normalized AUC of ABBV-295 will be assessed.

    Time frame: Up to approximately 194 days

  14. Incidence of Anti-Drug Antibodies (ADAs)

    Incidence of ADAs will be assessed.

    Time frame: Up to approximately 194 days

  15. Percent Change in Body Weight From Baseline

    Percent change in body weight (kg) will be assessed.

    Time frame: Up to approximately 194 days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 17 months is above that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Mar 2027 → Apr 2027 and completion Mar 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 18, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Apr 2027was Mar 2027
CompletionEst.
Apr 2027was Mar 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 5, 2026
Primary completion
Mar 2027→Apr 2027
Nov 5, 2026
Study completion
Mar 2027→Apr 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Mar 2027→Apr 2027
    Study completion Mar 2027→Apr 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07291232
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Nov 19, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-295

Start the discussion